Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Bayesian Pick-the-Winner Clinical Trial Investigating the Efficacy of Fibrosis-Modulating Agents (Paricalcitol and Pirfenidone) in Improving Surgical Resectability in Patients With Peritoneal Carcinomatosis Ineligible for Definitive Cytoreduction (Randy 1A)

NCT07856914 is registered in ClinicalTrials.gov with Patrick Wagner, MD, FACS as lead sponsor.

NCT NCT07856914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07856914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Bayesian Pick-the-Winner Clinical Trial Investigating the Efficacy of Fibrosis-Modulating Agents (Paricalcitol and Pirfenidone) in Improving Surgical Resectability in Patients With Peritoneal Carcinomatosis Ineligible for Definitive Cytoreduction (Randy 1A)
Lead sponsor
Patrick Wagner, MD, FACS
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
November 30, 2030
Enrollment
74 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

peritoneal (metastatic) cancer, peritoneal cancer, peritoneal carcinoma, peritoneal carcinomatosis, peritoneal carcinomatosis from colorectal or ovarian origin, peritoneal carcinosis, peritoneal cavity cancer